OmniAb, Inc. OABI 深 滬
已收盤 02-06 16:00:00 美东时间
1.70
+0.050
+3.03%
華盛通- 最 高1.72
- 今 開1.70
- 成交量 31.91万股
- 最 低 1.6707
- 昨 收 1.65
- 總市值 2.45亿
- 52周最高 4.02
- 市盈率 靜 --
- 換手率 0.22%
- 52周最低 1.22
- 委 比 93.70%
- 總股本 1.44亿
- 歷史最高 10.87
- 量 比 0.63
- 振 幅 2.99%
- 歷史最低 1.22
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
2025-12-11 23:17
OmniAb And Arrowmark Partners Sign A License And Services Agreement For Novel OmniAb-Derived Antibody Discovery Programs With Mabtrx Biosciences; OmniAb To Receive Revenue For Discovery Services As Well As Potential Equity And Royalties
OmniAb, Inc. (NASDAQ:OABI) and ArrowMark Partners ("ArrowMark") today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned
2025-11-18 06:28
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to b...
2025-08-26 19:12
OmniAb to raise $30M in private stock placement
OmniAb (NASDAQ:OABI) has entered into a definitive agreement for a private placement of its common stock to raise approximately $30 million in gross proceeds. The company will issue and sell a total o...
2025-08-25 19:34
OmniAb Announces $30M Private Placement Agreement
An update from OmniAb ( ($OABI) ) is now available. On August 24, 2025, OmniAb,...
2025-08-25 19:28
RBC Capital Maintains Outperform on OmniAb, Lowers Price Target to $3
RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers the price target from $4 to $3.
2025-08-07 23:11
CORRECTION: OmniAb Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $3.897M Miss $5.334M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 4.46 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the same
2025-08-07 06:51
OmniAb Affirms FY2025 Sales Guidance of $20.000M-$25.000M vs $22.970M Est
OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.000 million-$25.000 million to $20.000 million-$25.000 million vs $22.970 million estimate.
2025-08-07 05:54
AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul of health...
2025-06-30 21:50
